6 minute read
Mar. 26, 2024
Lirafugratinib (RLY-4008): The First Isoform-Selective FGFR2 Inhibitor with Potential Best-in-Class Properties
lirafugratinib (RLY-4008)
oral covalent FGFR2 inhibitor Ph. II for cholangiocarcinoma from rational design with MD simulations Cancer Discov., June 4, 2023 Relay Therapeutics, MA / D. E. Shaw Research, NY
Loading...
